

April 9, 2020

Pharma stocks poised for re-rating amid panic...

Amid Covid-19 pandemic panic that has taken a heavy toll on most sectors in the Indian markets, most pharma companies withstood the carnage while some, in fact, delivered positive returns during this period. Most sectors continued to suffer on account of unprecedented lockdowns and limited business continuity plans (BCPs) besides a bleak demand outlook. The cases of Covid-19 are still increasing with significant velocity in many parts of the world. There is significant uncertainty as to when things will normalise. However, in pharma, barring few supply related disturbances, we do not envisage material earnings impact in FY21. Also, note that in this unprecedented global lockdown, pharma and healthcare services, being at the top layer of essential services, remain exempted everywhere. Now that Chinese supply lines for key starting materials (KSM) and APIs are crawling back to normal, the supply side issues are slowly waning. Overall, we expect hindrances to persist for the next two to three months only with full normalcy from Q2FY21 onwards. Our FY21 earnings estimates for I-direct coverage universe are unlikely to change materially as will be FY22 estimates as there is no change in visibility aspect. However, we expect a multiple re-rating in some stocks, especially for those with 1) stable earnings visibility, 2) no balance sheet stress and strong return ratios, 3) having strong presence in some critical segments, besides 4) decent ESG quotient.

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical products- a case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases. Profitability is also likely to improve due to cooling off of raw material prices (crude based solvents) and continuous focus on cost rationalisation and MR productivity. Improving operating leverage is also likely to contribute to margin expansion. The companies are also moderating their capex plans to focus on better RoCE.

In the following discussion, we briefly touch upon some initial takeaways from the discussions / comments from the managements of respective sub-segments.

Domestic formulations – The demand in the domestic market is normal as of now but movements of MRs are restricted. To address this, companies are using telephonic and digital marketing channels to push products. We believe domestic growth is likely to emanate from price hikes and volume increase (albeit on lower base). However, nationwide lockdown/curfew can still lead to supply related issues such as availability of packing materials etc. Delay in new launches may also impact overall growth. We expect normalised growth from Q2FY21 onwards.

Export formulations – Till date the shipments are normal even in the worst impacted countries. However, a complete lockdown or restriction on any international trade may impact businesses in future. The beneficial impact of sharp rupee depreciation may take some time to soak in.

Return (%) Mcap								
Company	1M	3M	YTD	1Y	8-Apr			
Sun Pharma.Ind	9	-1	1	-6	104776			
Dr Reddy's Labs	16	27	28	33	61197			
Divi's Lab.	-3	18	18	29	57579			
Torrent Pharma.	16	37	38	42	42938			
Cipla	18	11	8	-2	41340			
Biocon	6	16	11	8	39288			
Abbott	12	37	34	139	37146			
Cadila Health.	31	35	38	2	35816			
Lupin	6	-7	-8	-11	31964			
Aurobindo Pharr	-14	-3	-4	-44	25673			
lpca Labs.	12	35	42	72	20424			
P fiz er	-4	6	1	29	19443			
Apollo Hospitals	-25	-14	-12	2	17585			
Sanofi	-4	6	4	24	16736			
Alembic Pharme	3	16	13	20	12081			
Ajanta Pharma	-6	34	40	34	11933			
Syngene Int.	-7	-12	-15	-6	10844			
Natco Pharma	-4	-4	-3	2	10473			
Fortis Health	-17	-8	-7	-9	9309			
Glenmark Pharn	-16	-31	-33	-64	6591			
Narayana Hruda	-13	-20	-10	28	5662			
Jubilant Life	-32	-40	-39	-54	5178			
Aster DM	-37	-38	-38	-36	4958			
FDC Ltd	-14	0	-2	24	3552			
Indoco Remedie	-4	27	19	13	2108			
Hikal	-23	-24	-22	-50	1104			
Hester Bio	-32	-31	-31	-28	850			
Healthcare Glob	-37	-33	-33	-66	623			
Shalby Ltd	-34	-43	-44	-62	564			
NGL Fine-Chem Source: Bloomberg	-19	-31	-24	-27	200			

	Return (%)						
Company	1M	3M	YTD	1Y	3Y	5Y	
S&-P 500 Pharm Ir	-4	-7	-8	1	7	5	
NASDAQ Biotech	-7	-8	-9	-3	5	-1	
S&P Pharmaceuti	-12	-19	-21	-14	-5	-9	
DJP harma and Bi	-5	-8	-8	0	6	3	
DJSTOXX Healthc	-3	-7	-6	9	7	3	
MSCI World Pharr	-4	-7	-7	5	8	3	
NSE Pharma	5	6	5	-8	-6	-9	

Source: Bloomberg

Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

MItesh Shah, CFA mitesh.sha@icicisecurities.com

Sudarshan Agarwal sudarshan.agarwal@icicisecurities.com

Sector Update

API/ CRAMs players – On the back of recurring issues in China like shutdown due to environmental concerns earlier and now due to Covid-19, most formulation manufacturers have started looking at India as an alternative source of APIs. This bodes well for API players. For discretionary CRAMs, however, the de-stocking at the client's level is likely to impact near-term spending of large pharma companies in early stage innovative products.

Raw materials – Due to the steep decline in Covid-19 cases in China and restoration of manufacturing (except from Hubei province where manufacturing has just began), supplies of raw materials are about to normalise. Raw material prices are also cooling off though they are still higher than historical levels. However, certain supply chain issues such as heavy congestion at major ports in China for disinfection of ships are likely to persist, thus causing delays in consignments.

Notwithstanding the out and out PE expansion, we prefer a stock specific approach. We categorised pharma coverage companies into following – India specific branded generic players, blended model with higher India branded contribution followed by US and other export destinations, blended model with higher US generics exports followed by India branded contribution and API and CRAMS players.

In our order of preference, we prefer India specific branded players on the back of 9-10% expected growth momentum without much sweat and BS pressure, favourable market dynamics with doctor prescription stickiness to the fore and lower perceived risk factors. **MNCs such as Abbott India, Sanofi and Pfizer are our preferred picks in this category.**

We also prefer blended model with higher India branded contribution followed by US and other export destinations where India remains the main growth engine and other geographies as auxiliary engines. This category also includes cases in which there could be windfall gain opportunities such as the latest case of first generic approval by the USFDA to Cipla's inhalation product, 'albuterol sulfate' (Proventil HFA) metered dose inhaler that is used to treat bronchospasm amid rise in demand for albuterol products during the ongoing Covid-19 pandemic. **Ipca Labs, Ajanta Pharma, Torrent and Cipla are our preferred picks from this category.**


Thirdly, we prefer B2B players like API and CRAMS manufacturing on account of a better regulatory track record, client validation and long term supply agreement with marquee customers and frontloading of capex with specific order book. Divi's Labs, Syngene and Hikal are our top picks from this category.

We remain neutral on US focused generic players and companies with blended model with higher US generics exposure as we believe the regulatory overhang, higher competition and weaker pricing power continue to act as a major headwind with lower or higher degree in the near term.


Exhibit 1: Change in valuation


Company	CMP	FY22E EPS	Multiple		Target Price		Rating	
		(₹	0 I d	New	0 I d	New	0 I d	New
Abbott India	17929	469	36	40	16880	18755	BUY	HOLD
Ajanta	1450	77	20	22	1525	1700	BUY	BUY
Alembic	638	31	20	22	620	685	HOLD	HOLD
Auro	455	56	8	9	435	500	HOLD	HOLD
Cadila	373	21	15	18	285	375	HOLD	HOLD
Cipla	564	28	18	22	490	610	HOLD	HOLD
D ivi's	2225	71	28	30	1990	2130	HOLD	HOLD
Dr Reddy's	3740	181	20	22	3520	3980	HOLD	HOLD
lpca	1612	79	20	24	1560	1900	BUY	BUY
Lupin	733	31	18	24	675	745	HOLD	HOLD
P fiz er Ltd	4320	159	30	35	4775	5570	BUY	BUY
Sanofi India	7394	220	35	40	7715	8815	HOLD	BUY
Sun	455	23	20	22	460	510	Hold	HOLD
Torrent	2444	92	22	26	2020	2395	HOLD	HOLD


Source: ICICI Direct Research, Bloomberg





Source: ICICI Direct Research, Bloomberg
















12000

Source: Bloomberg, ICICI Direct Research

Source: Bloomberg, ICICI Direct Research

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%; Hold: -5% to 15%; Reduce: -5% to -15%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

We /l, Siddhant Khandekar, Inter CA, Mitesh Shah, CFA, Sudarshan Agarwal, PGDM (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ00183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.